Boc-MLF
Based on 4 publication(s) in Google Scholar
Boc-MLF (Boc-Met-Leu-Phe-OH) is a competitive FPR1 antagonist. Boc-MLF inhibits fMLF-induced neutrophil activation through FPR. Boc-MLF inhibits receptor-induced inflammation and cell migration. Boc-MLF inhibits amniotic epithelial-mesenchymal transition. Boc-MLF reduces pro-inflammatory cytokine levels. Boc-MLF increases collagen expression in fetal membranes. Boc-MLF reverses fetal membrane epithelial cell collapse, increases villi, and reduces mucus attachment. Boc-MLF can be used in research on premature rupture of fetal membranes.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.36%
- No. CAS: 67247-12-5
- Fòrmula: C25H39N3O6S
- Peso molecular:509.66
-
Almacenamiento:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-P0224
N-Formyl-Met-Leu-PheTNF Receptor Inhibitor -
HY-P2355
BOC-FlFlFFPR Antagonist -
HY-P1122
Cyclosporin HFPR-1 Inhibitor -
HY-P1119
WRW4FPRL1 Antagonist -
HY-P1117
MMK1FPRL-1 Agonist -
HY-P1120
WKYMVmN-Formyl Peptide Receptor Agonist -
HY-P1116
PBP10Decapeptide -
HY-P1118
Ac9-25FPR Agonist -
HY-103472
FPR-A14FPR Agonist -
HY-101283
HCH6-1FPR1 Antagonist -
HY-110246
Quin C1FPR2/ALX Agonist -
HY-103472R
FPR-A14 (Standard)Reference Standard
Publications Citing Use of MedChemExpress (MCE) Boc-MLF
More
Actividad biológica
Descripciòn
In Vitro
Boc-MLF acts as a fairly specific FPR antagonist in human neutrophils, inhibiting fMLF-induced NADPH oxidase activity while only slightly affecting WKYMVM-induced activity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley (female; pregnant; 6 months old; 15-17 days gestation; 250-350 g)[2]
-
Dosage:5 mg/kg
-
Administration:intraperitoneal injection; once daily; 2 consecutive days
-
Result:In the LPS+BOC-MLF group, FPR1 expression in fetal membranes was decreased compared with the LPS group.
IL-6 levels in cardiac blood were decreased compared with the LPS group.
EMT was reversed compared with the LPS group, with changes in E-Cad and Vimentin expression opposite to those in the LPS group.
Collagen expression in fetal membranes was increased compared with the LPS group.
Scanning electron microscopy showed reversal of LPS effects, with slight plumping of fetal membrane epithelial cells, increased villi, and no obvious mucus.
- Phagocytosis Functional Assay
- Scratch/Wound-Healing Migration Assay
- RNA extraction experimental
- Cell migration
- Chemotaxis Gradient Chamber Assay 1
- Under-Agarose Cell Migration Assay
- Neural Crest/Neuronal Cell Migration Explant Assay
- Transwell/Boyden Chamber Migration Assay
- 3D Collagen/Hydrogel Matrix Migration Assay
- Research Protocol for Inflammation-related Diseases
- Cell-Exclusion Zone Migration Assay
- Chemotaxis Gradient Chamber Assay 2
Chemical Information
-
No. CAS 67247-12-5
-
Appearance Solid
-
Peso molecular 509.66
-
Fòrmula C25H39N3O6S
-
Color White to off-white
-
Synonyms
Boc-Met-Leu-Phe-OH
-
Sequence
{Boc}-Met-Leu-Phe
-
Sequence Shortening
{Boc}-MLF
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
World J Gastroenterol
Mechanism of annexin A1/N-formylpeptide receptor regulation of macrophage function to inhibit hepatic stellate cell activation through Wnt/β-catenin pathway. [Abstract]2023 Jun 14;29(22):3422-3439. PMID: 37389234 -
iScience
2023 Oct 6;26(11):108153. PMID: 37867938 -
Immunol Lett
Lenvatinib-resistant liver cancer-derived HSP90α-containing extracellular vesicles enhance drug resistance via macrophage CXCL8 secretion. [Abstract]2026 Apr:278:107122. PMID: 41349809 -
Solvente y solubilidad
In Vitro:
DMSO : ≥ 100 mg/mL (196.21 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.91 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.91 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (276 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9621 mL | 9.8105 mL | 19.6209 mL | 49.0523 mL |
| 5 mM | 0.3924 mL | 1.9621 mL | 3.9242 mL | 9.8105 mL | |
| 10 mM | 0.1962 mL | 0.9810 mL | 1.9621 mL | 4.9052 mL | |
| 15 mM | 0.1308 mL | 0.6540 mL | 1.3081 mL | 3.2702 mL | |
| 20 mM | 0.0981 mL | 0.4905 mL | 0.9810 mL | 2.4526 mL | |
| 25 mM | 0.0785 mL | 0.3924 mL | 0.7848 mL | 1.9621 mL | |
| 30 mM | 0.0654 mL | 0.3270 mL | 0.6540 mL | 1.6351 mL | |
| 40 mM | 0.0491 mL | 0.2453 mL | 0.4905 mL | 1.2263 mL | |
| 50 mM | 0.0392 mL | 0.1962 mL | 0.3924 mL | 0.9810 mL | |
| 60 mM | 0.0327 mL | 0.1635 mL | 0.3270 mL | 0.8175 mL | |
| 80 mM | 0.0245 mL | 0.1226 mL | 0.2453 mL | 0.6132 mL | |
| 100 mM | 0.0196 mL | 0.0981 mL | 0.1962 mL | 0.4905 mL |
Boc-MLF Related Classifications
HY-103473 Related Classifications
Powered by Bioz